171 results for "cognitive behavioral therapy"
Managing psychological distress in women with breast cancer: A systematic review of intervention trends in the past decade.
Asia-Pacific journal of oncology nursing – December 01, 2026
preprint
Summary
Remarkably, 57% of interventions significantly reduce psychological distress in breast cancer survivors. A review of 14 trials, involving 2,447 cancer survivors, found that multimodal approaches like mindfulness or VR psychotherapy effectively manage stress, improving quality of life. These interventions achieved small to large effects (Cohen's d = 0.44-1.54). Purely cognitive or unstructured digital programs offered limited psychological benefit. Effective support for breast cancer survivors requires comprehensive, theory-based strategies to alleviate distress.
Abstract
The rising incidence and survival rates of breast cancer have increased the number of breast cancer survivors (BCSs) experiencing psychological dis...
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes
European Neuropsychopharmacology – March 12, 2026
Summary
MDMA-assisted therapy shows promise for reducing PTSD symptoms, with a notable effect size of -1.19 across nine trials involving 298 participants. Additionally, it may alleviate dissociative symptoms (effect size -0.37) and enhance overall functioning (effect size -0.83). However, the evidence is limited, as most studies faced high bias risks and small sample sizes. Overall certainty in findings remains low, emphasizing the need for larger, more rigorous trials to fully understand MDMA-AT's potential benefits in treating PTSD.
Abstract
Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to...
State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
Journal of Traumatic Stress – March 12, 2026
Summary
MDMA-assisted psychotherapy has shown remarkable promise for treating posttraumatic stress disorder (PTSD), with response rates exceeding 60% and remission rates around 40% in recent trials involving over 300 participants. Despite these encouraging results, the U.S. Food and Drug Administration denied market approval in August 2024 due to concerns about evidence gaps. This review highlights methodological limitations, such as blinding challenges and a lack of active comparators, while suggesting future research should integrate MDMA with established trauma-focused therapies to enhance cognitive behavioral outcomes.
Abstract
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combine...
Balancing Innovation and Evidence: Reflections on Structured Protocols in MDMA-Assisted Therapy Versus a Principle-Guided, Patient-Directed Approach
Psychedelic Medicine – March 10, 2026
Summary
MDMA-assisted therapy has shown remarkable clinical effects, with response rates exceeding 70% and dropout rates below 10%. This innovative approach integrates MDMA into a broader therapeutic framework, combining nondrug sessions with the unique, nonlinear experiences elicited by the substance. Emphasizing patient direction and flexibility, this model contrasts sharply with rigid treatment protocols that may undermine its transformative potential. Prioritizing real-world evidence and optimizing treatment mechanisms is crucial for harnessing the full benefits of this promising therapy for post-traumatic stress disorder.
Abstract
There is growing interest in incorporating MDMA (3,4-Methylenedioxymethamphetamine) into structured, evidence-based cognitive-behavioral treatment ...
MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst?
Translation The University of Toledo Journal of Medical Sciences – February 17, 2026
Summary
MDMA-assisted psychotherapy shows significant promise for treating PTSD, especially in patients resistant to traditional therapies. Clinical trials indicate up to 67% of participants experience lasting symptom relief. The treatment appears to reduce amygdala activity and enhance hippocampal connectivity, promoting neuroplasticity. Additionally, MDMA's prosocial effects improve therapeutic relationships, crucial for effective outcomes. This dual-action model suggests that MDMA not only aids cognitive processing but also fosters emotional safety, enhancing interpersonal communication during therapy. Such insights could refine protocols and therapist training in psychedelic-assisted approaches.
Abstract
MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsiv...
At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis
OpenAlex – February 11, 2026
Summary
At-home ketamine-assisted therapy significantly reduces PTSD symptoms, with a 44.6% decrease in the average PCL-5 score among 374 adults after six sessions. The clinical response rate reached 79.7%, and 60.7% achieved remission. Among those with suicidal ideation, 83% reported improvement by session two, escalating to 85.2% by session six. Additionally, depression and anxiety scores dropped by over 51% and 50%, respectively. Side effects were minimal, occurring in only 4.3% of participants, highlighting the potential of telehealth-supported mental health interventions.
Abstract
Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult popul...
Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial
Mendeley Data – February 02, 2026
Summary
A compelling randomized controlled trial reveals a single psilocybin session dramatically boosts smoking cessation. Among 82 participants, 40.5% receiving this hallucinogen achieved prolonged abstinence at six months, versus just 10% using a nicotine patch. This medicine, administered without anesthesia, showed a 6.1 times higher likelihood of prolonged abstinence from nicotine. This novel approach in psychiatry offers robust promise for smoking cessation, with no serious adverse effects reported, presenting a powerful alternative to conventional treatments.
Abstract
BACKGROUND. Annual tobacco-related deaths are estimated at 480,000 in the US and 8 million worldwide, dwarfing mortality for all other drugs of abu...
Hallucinations Induced by Psychoactive Drugs: Mechanisms, Consequences, and Therapeutic Interventions
Acta Scientific Neurology – February 01, 2026
Summary
Hallucinogens like psilocybin and LSD affect millions globally, leading to serious health and societal issues. These substances can cause effects ranging from mild visual distortions to severe psychotic episodes, with lasting psychological impacts for many individuals. Early diagnosis is crucial, relying on clinical evaluations and toxicological tests to differentiate drug-induced hallucinations from psychiatric disorders. Effective treatments often include antipsychotics and cognitive behavioral therapy. A collaborative approach across neuroscience, psychiatry, and public health is essential for improving prevention and treatment strategies, benefiting both patients and society.
Abstract
Millions of people worldwide experience hallucinations caused by psychoactive substances.These hallucinations are a serious problem for both health...
The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
Psychiatric Research and Clinical Practice – January 14, 2026
Summary
Psilocybin treatments paired with genuine psychotherapy show promise for improving clinical outcomes, as evidenced by a strong therapeutic alliance correlating with better results in 75% of cases. The Compass Psychological Support Model (CPSM) integrates psychoeducation and psychological support through three phases: preparation, administration, and integration. Key principles emphasize trust, present-moment focus, and client autonomy. Emotional breakthroughs during sessions have been linked to a significant effect size of 0.85, highlighting the importance of psychological frameworks in enhancing psilocybin therapy's efficacy and patient outcomes.
Abstract
A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing s...
Mindfulness Components and Their Clinical Efficacy: A Critical Review of an Ongoing Debate.
Healthcare (Basel, Switzerland) – January 13, 2026
Summary
For lasting mental health benefits from mindfulness, cognitive and emotional regulation skills like acceptance appear more crucial than meditation alone. Mindfulness programs demonstrate moderate clinical efficacy in reducing anxiety, depression, and stress. However, reported effect sizes are often inflated due to methodological issues. While meditation is key, health education and informal practices also contribute significantly. When assessing its overall impact, mindfulness shows comparable benefits to established treatments like Cognitive Behavioral Therapy, but a balanced understanding is essential for appropriate integration into mental health care.
Abstract
The rapid expansion of mindfulness research has generated both enthusiasm and controversy regarding its actual clinical value. While meditation is ...
AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE
Asian Journal of Pharmaceutical and Clinical Research – January 07, 2026
Summary
Papaverine shows promise in protecting against ketamine-induced schizophrenia-like behaviors. In a study involving mice, 30 mg/kg of ketamine for 10 days led to significant behavioral changes, including increased immobility (up to 50% longer), cognitive deficits in the Morris water maze (reduced navigation speed by 40%), and altered anxiety levels. Treatment with papaverine (30 mg/kg) and clozapine (7.5 mg/kg) improved these symptoms and reversed biochemical alterations, such as oxidative stress markers. These findings highlight papaverine's potential neuroprotective effects in schizophrenia treatment.
Abstract
Objectives: Schizophrenia (SCZ) is characterized by significant impairments in perception and cognitive flexibility. Making accurate plans for ther...
Ketamine Combined With Psychotherapy as a Treatment for Resistant Depression in a Public European Hospital.
Brain and behavior – January 01, 2026
Summary
All nine patients with resistant depression showed improvement after eight weeks of ketamine infusions combined with psychotherapy. This promising treatment approach saw a 44% response rate, with participants' depression scores shifting from severe to moderate. Among those with suicidal ideation, over half experienced remission. This type of treatment, sometimes considered a form of psychedelic-assisted therapy, yielded sustained benefits; only 29% of monitored outpatients experienced mood deterioration within three months.
Abstract
Depression affects around 280 million people worldwide, and about 30% of patients have treatment-resistant depression. Ketamine has significant sci...
Understanding and Addressing Bullying in Children and Adolescents.
Journal of the Korean Academy of Child and Adolescent Psychiatry – January 01, 2026
Summary
Bullying profoundly impacts children and adolescents, causing significant psychological and social distress. A review of studies published between 2000 and 2024 highlights its global prevalence and diverse forms. This chronic stressor can dysregulate neurobiological systems, increasing vulnerability to anxiety and depression. Effective psychotherapy, including Cognitive behavioral therapy and Play therapy, helps mitigate bullying's effects and improve child well-being. Addressing bullying requires comprehensive strategies integrating psychological, educational, and legal efforts to foster safe environments.
Abstract
Bullying among children and adolescents is a complex and widespread problem with profound psychological, social, and legal implications. It include...
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
OpenAlex – January 01, 2026
Summary
Remarkably, a single 25 mg psilocybin dose, integrated with Acceptance and Commitment Therapy (a form of cognitive behavioral therapy), reduced binge eating frequency in all five adults with Binge-eating disorder over 14 weeks. This promising development in clinical psychology and psychiatry offers a new context for treating eating disorders. Participants reported improved anxiety and cognitive flexibility, with three (60%) also showing reduced BMI and no serious adverse effects. This medicine appears to enhance cognition and quality of life, potentially aiding relapse prevention for severe binge eating.
Abstract
Abstract Binge Eating Disorder (BED) is the most prevalent eating disorder and is associated with psychiatric comorbidities, health impairments, an...
Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation
Journal of Psychoactive Drugs – January 01, 2026
Summary
Credibility powerfully predicts daily nicotine users' willingness to engage with smoking cessation interventions, especially novel psychological support like psilocybin-assisted psychotherapy (β = 0.71). A survey of 534 individuals revealed that familiarity significantly boosts perceived credibility (β = 0.36 for psilocybin; β = 0.16 for standard pharmacotherapy or cognitive behavioral therapy). This perception, vital for clinical psychology and psychiatry, drives interest in pursuing abstinence. Past psychedelic use also influenced willingness to try psilocybin-based medicine (β = 0.10).
Abstract
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy ...
A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder
Online Publication Service of Würzburg University (Würzburg University) – January 01, 2026
Summary
Psilocybin shows promising potential as a treatment for severe, treatment-resistant Obsessive Compulsive Disorder (OCD), with symptom reductions ranging from 23% to complete remission in participants. In a randomized controlled trial involving multiple doses, improvements persisted for weeks to months post-treatment, particularly with higher doses linked to more profound mystical experiences. Notably, no severe side effects were reported. This highlights psilocybin's ability to address chronic OCD, offering hope for those unresponsive to traditional cognitive behavioral therapy and antidepressants.
Abstract
Obsessive Compulsive Disorder (OCD) is a prevalent mental disorder, with a lifetime prevalence of 2-3%, characterized by intrusive thoughts (obsess...
Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development
Preprints.org – December 19, 2025
Summary
Psilocybin holds significant promise for improving eating disorder treatment, where current cognitive behavioral therapy faces high patient dropout. This theoretical work in clinical psychology explores how psilocybin, as an adjunct, could enhance psychotherapeutic engagement. Its effects on cognition and emotional openness, alongside experiential learning, might make behavioral therapy more effective. A proposed intervention protocol outlines integrating this psychedelic medicine, offering a novel approach in psychiatry. This aims to advance treatment protocols and the study of psychedelics in medicine, paving the way for future clinical trials.
Abstract
Eating disorders (ED) remain challenging to treat, with high dropout and low remission rates in cognitive-behavioral therapy for EDs (CBT-ED). Psil...
Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders
OpenAlex – December 18, 2025
Summary
Imagine a therapy where a single psychedelic session could unlock rigid personality patterns. Psilocybin, known to induce lasting personality change, may revolutionize treatment for personality disorders. A new model, Psilocybin-Assisted Schema Therapy (PAST), combines psilocybin with established Schema Therapy. This approach aims to relax deep-seated maladaptive beliefs, fostering cognitive flexibility. PAST could enhance outcomes and reduce treatment duration for challenging Cluster B and C personality disorders, where current options are limited. This framework outlines future studies on its potential.
Abstract
Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical bu...
Table 1_Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.docx
OPAL (Open@LaTrobe) (La Trobe University) – December 10, 2025
Summary
A single dose of the hallucinogen psilocybin can profoundly shift how individuals with obsessive-compulsive disorder perceive their condition. Qualitative research, using interpretative phenomenological analysis with 12 participants from a randomized controlled trial, explored these experiences. Participants reported acute perceptual and psychological effects. Post-dosing, they experienced changes in OCD symptoms and their perspective on the disorder. This suggests psilocybin, within clinical psychology and with psychotherapist support, offers a novel approach in psychiatry by altering subjective experience, opening new avenues for understanding and treating OCD.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Frontiers in Psychiatry – December 10, 2025
Summary
Psilocybin, a potent hallucinogen, offers unique insights for treating obsessive-compulsive disorder. A qualitative analysis, using Interpretative phenomenological analysis, explored the subjective experiences of 12 individuals from a randomized controlled trial. Participants reported acute perceptual and emotional shifts, though sometimes blunted by OCD. Post-dosing, changes in OCD symptoms and a new perspective on the condition emerged. This work in clinical psychology and psychiatry, part of Psychedelics and Drug Studies, highlights psilocybin's potential in mental health, suggesting integration with psychotherapy approaches, considering the trial's placebo-controlled nature.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Dance-based interventions in clinical populations: not all are the same
Frontiers in Psychology – October 17, 2025
Summary
Dance therapy can significantly enhance emotional, cognitive, and social integration, showing promise for various clinical populations. For instance, interventions like dance movement psychotherapy (DMP) have been effective in addressing issues such as depression, anxiety, and autism. A minimum of two years of training is required for practitioners to deliver these therapies. Additionally, adapted dance programs promote inclusivity for individuals with disabilities, fostering creativity and community engagement. Overall, these diverse dance-based interventions underscore the therapeutic potential of the arts in health and well-being.
Abstract
Introduction Dance is described as a phenomenon in which the human body and its movement, that may have a symbolic or aesthetic value within a vari...
The Psychedelic Reset: How Psychedelics May Reshape the Corticostriatal Circuit in Anorexia Nervosa
Carleton undergraduate journal of science. – September 02, 2025
Summary
A compelling new approach suggests psychedelics could offer a profound "reset" for Anorexia nervosa. Current Psychology treatments and pharmacology often struggle with the disorder's deep-seated cognitive inflexibility and rigid eating patterns. However, promising evidence from Drug Studies, including animal and human trials, indicates psychedelics like psilocybin can modulate brain circuitry. This promotes cognitive flexibility and disrupts maladaptive decision-making, offering psychotherapists a novel tool. By facilitating a shift from habit-driven to goal-directed control, these interventions aim to provide a fundamental behavioral "reset" for individuals struggling with this challenging condition.
Abstract
Anorexia nervosa (AN) is an eating disorder characterized by compulsive eating restrictions and cognitive inflexibility, which is linked to dysregu...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation.
The journal of pain – July 21, 2025
Summary
Living with chronic pain often reshapes identity, hindering one's ability to find meaning. A new perspective suggests psilocybin could help individuals reframe their experience, fostering meaning-making and reducing self-pain enmeshment. By modulating self-perception, this approach aims to enhance engagement in rehabilitation, offering a novel path to improved physical and psychological well-being for those with chronic pain.
Abstract
Those living with chronic pain and comorbid functional disabilities are often confronted by a physically and emotionally transformative experience,...
Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease.
Alzheimer's research & therapy – July 15, 2025
Summary
Treating complex diseases like Alzheimer's may require a multi-pronged approach. A recent investigation explored if combining two specific drug types could offer an effective adjunctive treatment. Using a mouse model, researchers tested whether a combination of **Ketamine** and **Prucalopride** could improve cognitive decline and address **neuroinflammation**. Positively, this dual strategy significantly enhanced memory and reduced signs of **neurodegeneration**, suggesting a promising new multimodal therapy.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia. There are limited approved medications that delay cognitive decline or lessen neuropsych...
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – July 15, 2025
Summary
Sub-psychedelic doses of 5-MeO-DMT show remarkable safety and tolerability. A first-of-its-kind trial gave weekly sublingual doses to adults with moderate anxiety/depression. Results indicated rapid absorption, no drug accumulation, and only mild, transient side effects, without inducing full psychedelic effects. This fast-acting compound modulated brain activity, emerging as a promising candidate for future mental health therapies.
Abstract
This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of...
Females in Psychedelic Research: A Perspective for Advancing Research and Practice.
ACS pharmacology & translational science – July 11, 2025
Summary
Did you know a woman's hormonal state might significantly shape her psychedelic experience? It's proposed that hormones like estrogen and progesterone modulate brain chemistry, influencing how psychedelics work. Fluctuations across the menstrual cycle can alter receptor expression and mindset, impacting the intensity and therapeutic benefits of substances like psilocybin. By tracking these hormonal changes, research can achieve greater data accuracy and offer individualized care, leading to safer, more effective psychedelic therapies for women.
Abstract
The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current ...
A systematic review on the role of EEG and fMRI-Neurofeedback training in the treatment of substance use disorders and behavioral addiction.
Psychiatry research – July 01, 2025
Summary
Brain training through neurofeedback shows promising results in treating substance use disorders and addiction. By monitoring brain activity through EEG and fMRI technology, patients learn to control their neural patterns, leading to reduced drug cravings and improved mental health. Studies reveal that specific brain wave protocols help patients regain control over addictive behaviors, offering a drug-free treatment option.
Abstract
Neurofeedback (NF), a form of biofeedback, is used to enhance the self-regulation of brain functions by assessing brain activity and delivering fee...
Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience.
Brain and behavior – July 01, 2025
Summary
Psychedelics can profoundly shape personal experiences, influencing behavior and outlook. A qualitative analysis of 300 online accounts revealed three key phases: before ingestion, participants focused on knowledge and mental preparation; during the experience, they reported sensory distortions and emotional states; and after, a unified theme emerged reflecting lasting changes in perspective. Notably, factors like mindset and environmental support were crucial throughout. This highlights the importance of understanding the nuanced stages of psychedelic experiences to enhance well-being and eudaimonia in health psychology.
Abstract
The phenomenology of psychedelic experiences has been a long-standing point of interest to researchers. However, internal experience has been relat...
Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism
Magna Scientia Advanced Research and Reviews – June 28, 2025
Summary
Trauma and substance use are profoundly underdiagnosed and undertreated in individuals with Level 1 Autism. While promising psychedelic-assisted therapies (e.g., psilocybin, MDMA, ketamine) address PTSD, and digital mental health interventions improve access, their intersection with autistic needs remains critically underexplored. This psychology review proposes a neurodevelopmentally sensitive, hybrid model. It integrates digital mental health tools with psychedelic psychological interventions to enhance mental health and trauma healing for autistic populations, addressing critical gaps in clinical psychology and psychiatry.
Abstract
Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Leve...
The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – June 23, 2025
Summary
People with depression often hold pessimistic views that worsen their condition. A recent analysis explored if psilocybin therapy could shift these negative biases better than escitalopram. Patients with depression were given either psilocybin or daily escitalopram. Results showed psilocybin significantly boosted optimism and improved dysfunctional attitudes across multiple areas, including achievement, dependency, and self-control. While escitalopram also helped reduce pessimism about negative events and improved attitudes towards achievement, psilocybin demonstrated a broader and more substantial positive impact on cognitive biases linked to depression.
Abstract
Patients with Major Depressive Disorder (MDD) have more dysfunctional attitudes than healthy individuals and these pessimistic biases are correlate...
Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer's Disease Therapy.
Cells – June 19, 2025
Summary
A multi-pronged approach shows promise for Alzheimer's disease. A study investigated combining specific plant-derived bioactive compounds with the psychedelic N,N-Dimethyltryptamine. Using a *Caenorhabditis elegans* model, this combination significantly improved mobility, reduced protein plaques, and boosted resilience against oxidative stress. These positive results suggest a synergistic effect, offering a new therapeutic direction for complex neurodegenerative conditions.
Abstract
Alzheimer's disease (AD) is a chronic and complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and irrev...
Neurochemical, Neurocircuitry, and Psychopathological Mechanisms of PTSD: Emerging Pharmacotherapies and Clinical Perspectives.
ACS chemical neuroscience – June 10, 2025
Summary
Brain chemistry offers new hope for PTSD treatment. Recent advances show how trauma disrupts the brain's neurocircuitry, particularly affecting the hypothalamic-pituitary-adrenal axis and serotonin levels. Promising treatments include MDMA-assisted therapy, which helps regulate the glutamatergic system. These insights are transforming treatment approaches, offering better options for recovery.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition triggered by exposure to traumatic events, with complex neurobiologic...
The Evolution of Do-It-Yourself Brain Hacking: From Fringe to Frontier.
Cureus – June 01, 2025
Summary
Remarkably, self-directed brain hacking, once niche, now influences mainstream healthcare. This biohacking evolution, driven by a desire for cognitive optimization, saw early users explore nootropics, microdosing, and transcranial stimulation. Such personal neuroenhancement efforts, leveraging neurotechnology, have inspired regulated digital therapeutics. As programmable cognition becomes a reality, medical stewardship is vital for safe and effective advancements.
Abstract
Do-it-yourself (DIY) brain hacking has evolved from fringe experimentation to a cultural and clinical phenomenon reshaping how individuals interact...
The antidepressant-like activity of ketamine in the rat chronic mild stress model requires activation of cortical 5-HT 1A receptors.
Behavioural pharmacology – June 01, 2025
Summary
Ketamine's remarkable ability to rapidly treat depression may depend on specific brain receptors, offering new hope for faster-acting treatments. In a groundbreaking discovery, researchers found that ketamine quickly reversed depression-like behaviors in rats experiencing chronic mild stress, but only when certain serotonin receptors in the brain's prefrontal cortex remained active. When these receptors were blocked, ketamine lost its antidepressant effects.
Abstract
Ketamine displays efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model. It rapidly reverses anhedonia...
A Review of Treatment Modalities for Comorbid Neuropathic Pain and Depression.
Journal of integrative neuroscience – May 26, 2025
Summary
People experiencing chronic nerve pain are 3x more likely to develop depression, highlighting a crucial link between these conditions. New evidence reveals that treating both neuropathic pain and depression simultaneously yields better outcomes than addressing each separately. Multiple treatment approaches, from nerve-targeting medications to brain stimulation techniques, show promise in managing this challenging co-morbidity. The most effective solutions combine physical and behavioral therapies with targeted medications.
Abstract
Over the past years, a number of clinical and preclinical investigations have been documented, suggesting treatment strategies and pharmaceuticals ...
Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats.
Scientific reports – May 26, 2025
Summary
Psilocybin shows promise in treating severe depression by targeting unique biological pathways. In a groundbreaking experiment, rats prone to depression-like behavior received psilocybin treatments. The compound significantly reduced signs of despair and improved cognitive function. It also boosted thyroid hormones and affected brain cannabinoid receptors, suggesting multiple ways it may help fight treatment-resistant depression.
Abstract
Major depressive disorder (MDD) is a leading cause of disability that affects over 300 million people globally. Despite multiple antidepressant tri...
EEG Response to Sedation Interruption Complements Behavioral Assessment After Severe Brain Injury.
Annals of clinical and translational neurology – May 25, 2025
Summary
Brain activity patterns during brief pauses in sedation may reveal hidden signs of consciousness in comatose patients. By measuring EEG signals while temporarily stopping anesthesia, doctors can better predict recovery chances - even when patients show no visible response. This approach significantly improves prognosis accuracy compared to traditional behavioral assessments alone.
Abstract
Accurate assessment of the level of consciousness and potential to recover in patients with severe brain injury underpins crucial decisions in the ...
Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes
Frontiers in Psychology – May 15, 2025
Summary
Aesthetic experiences during psychedelic use, like with psilocybin, significantly boost psychological insight (r=.48) and emotional breakthrough (r=.40). A survey of 96 individuals revealed that strong aesthetic and sensory perception predicted better quality of life and reduced anxiety, while also lessening paranoia (r=-.36). This suggests the aesthetic dimension, crucial for clinical psychology and psychotherapist practice, actively enhances cognition and well-being, influencing therapeutic outcomes in psychedelics and drug studies.
Abstract
Introduction The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes ...
A quasiexperimental study of assessing the impact of stress management program on health science students at Kuwait University.
Scientific reports – May 12, 2025
Summary
A comprehensive stress management program significantly improved mental health among 56 students at Kuwait University's Health Science Center. Participants reported a notable reduction in depression and stress levels, with 82.1% finding the program useful and 89.3% recommending it to peers. The program covered essential topics like meditation, cognitive behavioral therapy, and coping strategies. With a total of 98 participants, these findings highlight the effectiveness of culturally relevant interventions in managing anxiety and promoting well-being among students in demanding academic environments.
Abstract
The purpose of this research was to study the effectiveness of a stress management program among students at the Health Science Center (HSC), Kuwai...
Esketamine alleviates cognitive impairment signs induced by modified electroconvulsive therapy in a depression rat model via the KLF4/p38 MAPK pathway.
Journal of affective disorders – May 01, 2025
Summary
Promising breakthrough: Esketamine shows potential to protect brain function during electroconvulsive therapy for depression. The drug helps preserve memory and thinking abilities by activating protective pathways in the brain. Lab tests revealed it shields nerve cells while maintaining the therapy's antidepressant benefits.
Abstract
Depression is a common and serious psychiatric disorder with significant impacts on individuals. Modified electroconvulsive therapy (MECT) is an es...
Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.
Journal of psychiatric practice – May 01, 2025
Summary
Psilocybin combined with cognitive behavioral therapy showed dramatically different outcomes in treating major depressive disorder: one patient experienced lasting relief while another saw minimal benefits. The treatment involved two psilocybin sessions paired with CBT over seven months. The successful case demonstrated immediate and sustained mood improvement, while the other patient struggled with the drug/psychotherapy combination, highlighting how individual responses can vary significantly.
Abstract
We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major d...
An Update on Psychotherapy for the Treatment of PTSD.
The American journal of psychiatry – May 01, 2025
Summary
Trauma-focused psychotherapy remains the gold standard for treating Posttraumatic Stress Disorder (PTSD), outperforming medication-only approaches. While medications like sertraline help some patients, evidence shows that specialized psychotherapy techniques can rewire trauma responses in the brain, leading to lasting recovery. Top treatments include prolonged exposure and cognitive processing therapy, with success rates reaching 60-70% when properly implemented.
Abstract
Posttraumatic stress disorder (PTSD) symptoms are part of the normal response to trauma. Most trauma survivors will recover over time without inter...
Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder
Journal of Psychiatric Practice – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, shows highly variable effects for major depressive disorder. In a clinical trial, two patients received 12 cognitive therapy sessions and psilocybin (10mg, 25mg). One experienced immediate, sustained antidepressant effects over seven months, demonstrating its psychiatric promise. Yet, the other encountered significant challenges, with minimal therapeutic benefit. This divergence highlights the critical role of individual psychology and psychosocial factors, guiding psychotherapists in clinical psychology for optimal cognition in future psychedelic medicine.
Abstract
We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major d...
Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises
Molecular Psychiatry – April 26, 2025
Summary
Psilocybin therapy significantly reduces anhedonia in Major Depressive Disorder, a key insight for **Psychology** and **Psychiatry**. A **Clinical Psychology** investigation involved 41 patients with **Depression**, receiving either psilocybin (**Psychedelics and Drug Studies**) (n=22) or **Escitalopram** (n=19) over six weeks. Using **Functional magnetic resonance imaging** during **Audiology** tasks, **Neuroscience** revealed distinct **Treatment** mechanisms. While escitalopram reduced emotional responses to musical surprises, psilocybin maintained them. This suggests psilocybin influences **Cognitive Processes** differently, via **Neurotransmitter Receptor Influence on Behavior**, offering varied **Psychometrics** outcomes for **Anxiety** and depression.
Abstract
Abstract Psilocybin therapy (PT) is emerging as an effective intervention for Major Depressive Disorder (MDD), offering comparable efficacy to conv...
Characterization of responders to transcranial direct current stimulation in disorders of consciousness: A retrospective study of 8 clinical trials.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics – April 18, 2025
Summary
Brain stimulation therapy shows promise for patients with impaired consciousness, with 32% of minimally conscious patients regaining new signs of awareness. This breakthrough uses tDCS neuromodulation, delivering mild electrical currents to specific brain regions. The treatment proved most effective in patients with higher baseline cognitive function, particularly those in a minimally conscious state. Behavioral assessments revealed better outcomes for these tDCS responders compared to unresponsive patients.
Abstract
The treatment for patients with disorders of consciousness challenges researchers and clinicians. The stimulation of the left dorsolateral prefront...
Ketamine's Influence on Magnetoencephalography Patterns During a Working Memory Task in Treatment-Resistant Depression: An Exploratory Study.
Bipolar disorders – April 02, 2025
Summary
Ketamine, a promising treatment for severe depression, changes brain wave patterns in memory-related regions while leaving cognitive performance intact. In patients with treatment-resistant depression, a single dose improved mood without affecting working memory or attention. Brain scans revealed shifts in neural activity across key attention networks, suggesting ketamine's antidepressant effects work through unique pathways that preserve cognitive function.
Abstract
Treatment-resistant depression (TRD) remains a challenge, necessitating novel interventions that address associated cognitive deficits. The glutama...
Ketamine Treatment for Pediatric Refractory Obsessive: Five Open Label Cases.
Journal of child and adolescent psychopharmacology – April 01, 2025
Summary
A single ketamine infusion shows promise as a safe treatment option for teens with severe OCD (obsessive-compulsive disorder). In a groundbreaking trial, five adolescents who hadn't responded to standard treatments received controlled doses. While the immediate reduction in OCD symptoms wasn't sustained long-term, the treatment proved remarkably safe with only mild, temporary side effects.
Abstract
Importance: Selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy are the first-line treatments for pediatric obsessive-...
MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward.
CNS drugs – April 01, 2025
Summary
MDMA-assisted therapy shows remarkable promise in treating PTSD, with nearly 70% of participants experiencing such significant improvement that they no longer met diagnostic criteria. This breakthrough approach combines psychotherapy with carefully administered MDMA doses, creating a therapeutic window where patients can process trauma more effectively. Despite positive clinical results, regulatory hurdles remain due to concerns about trial design and safety protocols.
Abstract
Trauma is prevalent, with lifetime estimates of traumatic exposure ranging from 70% for a single event to 31% for multiple events. While many recov...
Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.
Pharmaceuticals (Basel, Switzerland) – March 29, 2025
Summary
Recent clinical research shows LSD works by activating specific serotonin receptors in the brain, producing profound effects on mood and consciousness. When combined with therapy, this psychedelic medicine significantly reduced anxiety and depression in 79% of participants. Studies reveal that a single supervised session can create lasting positive changes in mental health and addiction recovery.
Abstract
Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clini...